Australia - English - Department of Health (Therapeutic Goods Administration)

clinect pty ltd - methylene blue, quantity: 50 mg - injection - excipient ingredients: water for injections - proveblue is indicated: for the treatment of drug-induced methaemoglobinaemia. for the treatment of idiopathic methaemoglobinaemia (in which structural abnormality of haemoglobulin is not present). as a bacterial stain. as a dye in diagnostic procedures such as fistula detection. for the delineation of certain body tissues during surgery.

Canada - English - Health Canada

phebra pty ltd - methylene blue - solution - 10mg - methylene blue 10mg - antidotes

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

aristopet pty ltd - methylene blue - misc. fish tank medication - methylene blue dye-blue active 12.0 mg/ml - parasiticides - fish aquarium freshwater | fish egg | cold water | tropical - fungal infection | white spot | whitespot

Canada - English - Health Canada

hikma canada limited - methylene blue - solution - 10mg - methylene blue 10mg - antidotes

United States - English - NLM (National Library of Medicine)

vifor (international) inc. - methoxy polyethylene glycol-epoetin beta (unii: lr3uxn0193) (methoxy polyethylene glycol-epoetin beta - unii:lr3uxn0193) - methoxy polyethylene glycol-epoetin beta 30 ug in 0.3 ml - mircera is indicated for the treatment of anemia associated with chronic kidney disease (ckd) in: limitations of use mircera is not indicated and is not recommended: mircera has not been shown to improve symptoms, physical functioning, or health-related quality of life. mircera is contraindicated in patients with: risk summary available data from a small number of published case reports and postmarketing experience with mircera use in pregnancy are insufficient to identify a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. chronic kidney disease is associated with maternal and embryo-fetal risks (see clinical considerations) . in animal reproduction studies, administration of methoxy polyethylene glycol-epoetin beta to rats and rabbits during pregnancy and lactation adversely affected offspring at doses 17-fold and greater than the recommended human dose (see data) . the estimated background risk of major birth defects and miscarriage for the indicated populatio

United States - English - NLM (National Library of Medicine)

lupin pharmaceuticals,inc. - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p), sodium chloride (unii: 451w47iq8x) (chloride ion - unii:q32zn48698), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152), sodium bicarbonate (unii: 8mdf5v39qo) (sodium cation - unii:lyr4m0nh37), sodium sulfate anhydrous (unii: 36kcs0r750) (sodium sulfate anhydrous - unii:36kcs0r750) - polyethylene glycol 3350 240 g in 278.26 g - gavilyte- c with flavor pack is indicated for bowel cleansing prior to colonoscopy or barium enema x-ray examination. gavilyte- c with flavor pack is contraindicated in patients known to be hypersensitive to any of the components. gavilyte- c with flavor pack is contraindicated in patients with ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis or toxic megacolon.

United States - English - NLM (National Library of Medicine)

lannett company, inc. - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152), sodium bicarbonate (unii: 8mdf5v39qo) (sodium cation - unii:lyr4m0nh37), sodium sulfate (unii: 0ypr65r21j) (sodium cation - unii:lyr4m0nh37) - polyethylene glycol 3350 240 g in 4 l - peg-3350 & electrolytes is indicated for bowel cleansing prior to colonoscopy or barium enema x-ray examination. peg-3350 & electrolytes is contraindicated in patients known to be hypersensitive to any of the components. peg-3350 & electrolytes is contraindicated in patients with ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis or toxic megacolon.

United States - English - NLM (National Library of Medicine)

strategic sourcing services llc - polyethylene glycol 400 (unii: b697894sgq) (polyethylene glycol 400 - unii:b697894sgq), propylene glycol (unii: 6dc9q167v3) (propylene glycol - unii:6dc9q167v3) - polyethylene glycol 400 0.4 g in 100 ml - purpose polyethylene glycol 400............. lubricant propylene glycol............ lubricant uses • for the temporary relief of burning and irritation due to dryness of the eye

United States - English - NLM (National Library of Medicine)

atlantic biologicals corps - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p) - for the treatment of occasional constipation. this product should be used for 2 weeks or less or as directed by a physician. polyethylene glycol 3350 nf is contraindicated in patients with known or suspected bowel obstruction and patients known to be allergic to polyethylene glycol.

United States - English - NLM (National Library of Medicine)

oceanside pharmaceuticals - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p), sodium sulfate (unii: 0ypr65r21j) (sodium sulfate anhydrous - unii:36kcs0r750), sodium chloride (unii: 451w47iq8x) (chloride ion - unii:q32zn48698), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - polyethylene glycol-3350, electrolytes, and ascorbate for oral solution is an osmotic laxative indicated for cleansing of the colon as a preparation for colonoscopy in adults. polyethylene glycol-3350, electrolytes, and ascorbate for oral solution is contraindicated in the following conditions: risk summary there are no available data on polyethylene glycol-3350, electrolytes, and ascorbate for oral solution in pregnant women to inform a drug-associated risk for adverse developmental outcomes. animal reproduction studies have not been conducted with polyethylene glycol-3350, electrolytes, and ascorbate for oral solution. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. risk summary the